Sintilimab

Generic Name
Sintilimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2072873-06-2
Unique Ingredient Identifier
8FU7FQ8UPK
Associated Conditions
-
Associated Therapies
-
onclive.com
·

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer

China's NMPA granted conditional approval to fruquintinib plus sintilimab for advanced endometrial cancer patients with previous systemic therapy failure, based on the FRUSICA-1 study. The combination showed an ORR of 35.6% and a DCR of 88.5%, with a median PFS of 9.5 months and median OS of 21.3 months. This approval aims to improve survival and quality of life for patients with limited treatment options.
prnewswire.com
·

Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024

Innovent Biologics to present 10 clinical data on novel oncology molecules at ESMO Asia 2024, including updated Phase 1 results of IBI343 in pancreatic cancer.
nature.com
·

Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial

Neoadjuvant ori+tori therapy in resectable stage III and IVM1a acral melanoma (AM) showed 77.8% pathological response, 85.2% 1-year RFS, and 81.5% 2-year RFS, surpassing previous adjuvant therapy alone. Limited data exist on adjuvant or neoadjuvant settings for AM, with most from retrospective studies showing RFS from 14.8 to 26 months. The NADINA study demonstrated neoadjuvant ipilimumab and nivolumab improved EFS over adjuvant nivolumab. AM is less responsive to immunotherapy; anti-PD-1 monotherapy ORR was 18.0% with median PFS of 3–5 months. Combination therapy of anti-PD-1 with oncolytic virus showed 77.8% pathological response, suggesting potential in advanced AM. Oncolytic virus modifies tumor microenvironment, enhancing immune cell activity and sensitivity to immunotherapy. Pathologic response is critical for neoadjuvant therapy efficacy; neoadjuvant ori+tori offered significant advantages over oncolytic virus monotherapy. Safety profiles were favorable, with 13.3% grade 3 AEs. PET/CT showed no correlation with pathological response, necessitating new evaluation technologies. These preliminary data encourage further controlled trials, especially in unresectable metastatic AM.
globenewswire.com
·

HUTCHMED Highlights Clinical Data to be Presented at the

HUTCHMED announces new data from the sovleplenib ESLIM-01 Phase III trial and several investigator-initiated studies will be presented at the 2024 ASH Annual Meeting and ESMO Asia Congress. Long-term safety and efficacy data from the ESLIM-01 sub-study showed sovleplenib effectively increased and maintained platelet count in chronic primary ITP patients, with a well-tolerated safety profile.
nature.com
·

Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable ...

Articles discuss various treatments for hepatocellular carcinoma, including immunotherapies, stereotactic body radiotherapy, and combinations with checkpoint inhibitors. Topics include global cancer statistics, management of portal vein tumor thrombosis, and guidelines for diagnosis and treatment. Key studies highlight the efficacy and safety of different therapies, such as atezolizumab plus bevacizumab, and the potential synergies between radiotherapy and immunotherapy.
nature.com
·

Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non

45 patients received sintilimab plus anlotinib concurrent with platinum-based doublet chemotherapy; 34 had squamous cell carcinoma, 33 stage III disease. 26 achieved pathologic complete response (pCR), 30 major pathologic response (MPR). Objective response rate (ORR) was 71.1%, disease control rate (DCR) 97.8%. Median follow-up was 22.8 months, with 24-month event-free survival (EFS) rate of 81.5%. All-grade treatment-related adverse events (TRAEs) occurred in 100% of patients, with immune-related AEs (irAEs) in 15.6%. Neoadjuvant treatment significantly decreased Treg cell infiltration and increased vascular normalization and perivascular CD4+ T cell infiltration in pCR patients.

Lymph node ratio is a prognostic indicator for locally advanced gastric cancer after ...

121 LAGC patients underwent radical resection post-NICT; mean age 58.3 ± 9.4 years, 78.5% male. LNR correlated with lymphovascular/perineural invasion, ypT/ypN stage, pCR, MPR, PLNs. Low LNR linked to better 2-year OS (88.5% vs. 32.6%) and PFS (80.2% vs. 23.5%). LNR independent prognostic factor for OS and PFS, outperforming ypN stage.
nature.com
·

Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based ...

Studies on nasopharyngeal carcinoma (NPC) include evolving paradigms, incidence and mortality, web-based nomograms for survival prediction, chemoradiotherapy comparisons, long-term outcomes, immunotherapy prospects, induction chemotherapy effects, final overall survival analyses, prognostic factors, staging system validations, and the role of EBV-DNA in treatment and prognosis.

Clinical study on conversion therapy of hepatocellular carcinoma

10% of HCC patients with ideal resection globally, 19.2% achieved R0 resection in recent year. Conversion therapy enabled 28% initially unresectable HCC patients to undergo R0 resection. Clinical trials show high conversion rates, but real-world conversion rate is 1.81%. Conversion surgery patients had longer operation times and hospital stays but comparable survival prognosis to direct surgery patients.
© Copyright 2024. All Rights Reserved by MedPath